FUNDAMENTALS · Fundamentals · US Healthcare

Celcuity (CELC) Fundamentals 2026 — Revenue Analysis | SniperIQ

Celcuity (CELC) is a US-listed Healthcare company in Biotechnology with a market capitalization of $4.4B, trading at $90.30 on the NASDAQ. This SniperIQ fundamentals page covers Celcuity's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$4.4B
Net Margin0.0%

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Celcuity's market cap?

Celcuity (CELC) has a market capitalization of approximately $4.4B, trading at $90.30 on the NASDAQ. Market cap moves with the live share price.

What is Celcuity's P/E ratio?

Celcuity's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 91.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Celcuity?

Celcuity runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Celcuity pay a dividend?

Celcuity does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Celcuity financially healthy?

Celcuity carries a debt-to-equity ratio of 3.65x and a current ratio of 12.31x, with a market beta of 0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Celcuity a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Celcuity (CELC) the key facts are: market cap $4.4B, 52-week range 13.59-151.02. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Celcuity's full fundamentals live

Get Celcuity's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Getein Biotech (603387) fundamentals · Fuan Pharmaceutical (Group) (300194) fundamentals · Sinew Pharma (6634) fundamentals · Beijing Beilu Pharmaceutical (300016) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons